GendiAG Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

GendiAG General Information

Description

Provider of genetic diagnostic and personalized-medicine services designed for clinical and research applications. The company develops and markets diagnostic services and genomics-based assays for disease predisposition, early diagnosis, prognosis, and drug-response prediction, leveraging biochip/microarray technology and collaborative research alliances, enabling hospitals, clinics, pharmaceutical companies, and research institutions global access to advanced genetic diagnostics and personalized-medicine support.

Contact Information

Website
www.gendiag.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Calle Lepant 141 P 4 Pta 1
  • 10 Joan Xxiii, Esplugues De Llobregat
  • 08013 Barcelona
  • Spain
Primary Industry
Biotechnology
Parent Company
GENinCode
Corporate Office
  • Calle Lepant 141 P 4 Pta 1
  • 10 Joan Xxiii, Esplugues De Llobregat
  • 08013 Barcelona
  • Spain

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GendiAG Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GendiAG‘s full profile, request access.

Request a free trial

GendiAG Patents

  • 40

    Total Documents Applications and Grants

  • Total Patents Families

  • 19

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

GendiAG Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2018215590-A1 Cancer-associated venous thromboembolic events Inactive 24-May-2017
EP-2957634-A1 Compounds for prevention and/or treatment of fibrotic diseases Inactive 20-Jun-2014
AU-2014314097-A1 Risk markers for cardiovascular disease in patients with chronic kidney disease Inactive 30-Aug-2013
CA-2922329-A1 Risk markers for cardiovascular disease in patients with chronic kidney disease Inactive 30-Aug-2013
JP-2016528907-A Risk markers for cardiovascular disease in patients with chronic kidney disease Pending 30-Aug-2013 C12Q1/6883
To view GendiAG’s complete patent history, request access »

GendiAG Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GendiAG‘s full profile, request access.

Request a free trial

GendiAG FAQs

  • When was GendiAG founded?

    GendiAG was founded in 2006.

  • Where is GendiAG headquartered?

    GendiAG is headquartered in Barcelona, Spain.

  • What industry is GendiAG in?

    GendiAG’s primary industry is Biotechnology.

  • Is GendiAG a private or public company?

    GendiAG is a Private company.

  • What is GendiAG’s current revenue?

    The current revenue for GendiAG is .

  • Who are GendiAG’s investors?

    Ferrer Internacional has invested in GendiAG.

  • When was GendiAG acquired?

    GendiAG was acquired on 12-Sep-2018.

  • Who acquired GendiAG?

    GendiAG was acquired by GENinCode.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process